Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.33 |
| ▸ | PDE4A | P27815 | 4/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.33 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | GAK | O14976 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563533 | 0.91 | PIK3CA (0.38) | EGFRPIK3CAMBOAT4PDE4DPDE4A | |
| SCHEMBL563714 | 0.85 | EGFR (0.34) | EGFRPIK3CAPDE4DPDE4APDE4B | |
| SCHEMBL564669 | 0.81 | BRD4 (0.38) | PIK3CAMBOAT4PDE4DPDE4APDE4B | |
| SCHEMBL15309160 | 0.79 | MKNK1 (0.36) | EGFRPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL15309159 | 0.79 | MKNK1 (0.36) | EGFRPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL563661 | 0.79 | PDE4D (0.35) | PIK3CAPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL564327 | 0.79 | APP (0.32) | EGFRPIK3CAPDE4DPDE4APDE4B | |
| SCHEMBL564373 | 0.77 | PDE4D (0.38) | EGFRPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL564372 | 0.77 | MKNK1 (0.36) | EGFRPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL564734 | 0.76 | ALDH1A1 (0.36) | PIK3CAPDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557805-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| EP-2371826-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | GPR119, GCKR, SLC5A1 | EGFR 4646/4885PIK3CA 875/4885MBOAT4 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.